Immuron (IMRN) Share-based Compensation (IS) (2017 - 2023)
Immuron's quarterly Share-based Compensation (IS) came in at $2.0 million in Q3 2023, up 1249.86% quarter-over-quarter from $151687.1 in Q2 2023.
Immuron has reported Share-based Compensation (IS) for 6 years, with the latest figure at $2.0 million in Q3 2023.
- For the quarter ending Q3 2023, Share-based Compensation (IS) changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Sep 2023 stood at $2.0 million (changed N/A YoY), and the FY2023 full-year result was $2.0 million, changed N/A from the prior year.
- Share-based Compensation (IS) for Q3 2023 stood at $2.0 million, up from $151687.1 in the prior quarter.
- The five-year high for Share-based Compensation (IS) was $2.0 million in Q3 2023, with the low at -$42.7 billion in Q4 2021.
- Average Share-based Compensation (IS) over 5 years is -$5.3 billion, with a median of $109827.2 recorded in 2023.
- Year-over-year, Share-based Compensation (IS) sank 201692833.78% in 2021 and jumped 123.18% in 2023.
- Tracing IMRN's Share-based Compensation (IS) over 5 years: stood at $6070.0 in 2019, then sank by 448.6% to -$21160.1 in 2020, then slumped by 201692833.78% to -$42.7 billion in 2021, then jumped by 100.0% to $2.0 million in 2022, then climbed by 2.07% to $2.0 million in 2023.
- The last three Share-based Compensation (IS) figures came in at $2.0 million (Q3 2023), $151687.1 (Q2 2023), and $2.0 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.45 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 14.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 28, 2023 | 2.05 Mn |
| Sep 28, 2023 | 2.05 Mn |
| Jun 30, 2023 | 151,687.08 |
| Jun 30, 2023 | 151,687.08 |
| Dec 31, 2022 | 2.01 Mn |
| Dec 31, 2022 | 2.01 Mn |
| Jun 30, 2022 | 67,967.42 |
| Jun 30, 2022 | 67,967.42 |
| Dec 31, 2021 | -42.68 Bn |
| Dec 31, 2021 | -42.68 Bn |
| Jun 30, 2021 | 1.63 Mn |
| Jun 30, 2021 | 1.63 Mn |
| Dec 31, 2020 | -21,160.13 |
| Dec 31, 2020 | -21,160.13 |
| Dec 31, 2019 | 6,070.00 |
| Dec 31, 2019 | 6,070.00 |
| Dec 31, 2017 | -46,380.23 |
| Dec 31, 2017 | -46,380.23 |